Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLT Applied Therapeutics	$0.34 -0.4%	$0.39	$0.30 ▼ $10.62	$45.30M	1.82	3.44 million shs	1.86 million shs
CYTK Cytokinetics	$33.90 -1.3%	$33.28	$29.31 ▼ $61.38	$4.14B	0.59	1.52 million shs	1.30 million shs
GOSS Gossamer Bio	$1.23 +1.2%	$1.19	$0.66 ▼ $1.55	$281.85M	1.86	1.46 million shs	433,035 shs
KPTI Karyopharm Therapeutics	$4.62 +0.2%	$4.97	$3.51 ▼ $16.95	$37.93M	0.24	76,706 shs	36,017 shs
PHAT Phathom Pharmaceuticals	$8.77 -1.6%	$6.25	$2.21 ▼ $19.71	$622.74M	0.45	1.55 million shs	499,121 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLT Applied Therapeutics	0.00%	+4.08%	-7.37%	-22.51%	-92.31%
CYTK Cytokinetics	0.00%	+2.23%	+5.67%	-9.26%	-37.68%
GOSS Gossamer Bio	0.00%	-2.00%	-2.78%	+53.13%	+18.93%
KPTI Karyopharm Therapeutics	0.00%	+5.24%	+8.45%	+19.69%	-62.81%
PHAT Phathom Pharmaceuticals	0.00%	-10.01%	+86.89%	+79.61%	-14.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLT Applied Therapeutics	3.8147 of 5 stars	3.3	1.0	4.7	0.6	1.7	1.3
CYTK Cytokinetics	3.9341 of 5 stars	4.5	2.0	4.6	0.0	0.8	0.0
GOSS Gossamer Bio	3.66 of 5 stars	3.5	1.0	4.7	1.5	1.7	0.0
KPTI Karyopharm Therapeutics	3.8397 of 5 stars	3.5	1.0	4.6	0.6	2.5	0.6
PHAT Phathom Pharmaceuticals	3.6013 of 5 stars	4.5	1.0	0.0	1.1	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLT Applied Therapeutics	2.50	Moderate Buy	$6.10	1,710.09% Upside
CYTK Cytokinetics	2.93	Moderate Buy	$70.92	109.21% Upside
GOSS Gossamer Bio	3.00	Buy	$7.33	498.64% Upside
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	835.06% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	99.66% Upside

Current Analyst Ratings Breakdown

Latest PHAT, APLT, KPTI, CYTK, and GOSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	CYTK Cytokinetics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$71.00 ➝ $53.00
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
5/29/2025	CYTK Cytokinetics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$103.00 ➝ $84.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/14/2025	APLT Applied Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$1.50 ➝ $1.50
5/14/2025	CYTK Cytokinetics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00
5/13/2025	CYTK Cytokinetics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLT Applied Therapeutics	$265K	180.04	N/A	N/A	$0.49 per share	0.69
CYTK Cytokinetics	$18.47M	219.20	N/A	N/A	($1.15) per share	-29.48
GOSS Gossamer Bio	$114.70M	2.43	N/A	N/A	$0.13 per share	9.42
KPTI Karyopharm Therapeutics	$145.24M	0.27	N/A	N/A	($22.10) per share	-0.21
PHAT Phathom Pharmaceuticals	$55.25M	11.07	N/A	N/A	($3.71) per share	-2.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLT Applied Therapeutics	-$105.62M	-$0.43	N/A	N/A	N/A	N/A	-184.67%	-84.02%	8/6/2025 (Estimated)
CYTK Cytokinetics	-$589.53M	-$5.29	N/A	N/A	N/A	-3,201.47%	N/A	-43.75%	8/6/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$13.26	N/A	N/A	N/A	-43.99%	N/A	-35.95%	8/5/2025 (Estimated)
PHAT Phathom Pharmaceuticals	-$334.33M	-$5.24	N/A	N/A	N/A	-422.42%	N/A	-90.11%	8/6/2025 (Estimated)

Latest PHAT, APLT, KPTI, CYTK, and GOSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
5/6/2025	Q1 2025	CYTK Cytokinetics	-$1.41	-$1.36	+$0.05	-$1.36	$2.77 million	$1.60 million
4/14/2025	Q4 2024	APLT Applied Therapeutics	-$0.18	-$0.24	-$0.06	$0.33	$0.61 million	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLT Applied Therapeutics	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLT Applied Therapeutics	N/A	3.00	3.00
CYTK Cytokinetics	N/A	5.99	5.99
GOSS Gossamer Bio	6.70	5.71	5.71
KPTI Karyopharm Therapeutics	N/A	1.33	1.28
PHAT Phathom Pharmaceuticals	N/A	3.58	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLT Applied Therapeutics	98.31%
CYTK Cytokinetics	N/A
GOSS Gossamer Bio	81.23%
KPTI Karyopharm Therapeutics	66.44%
PHAT Phathom Pharmaceuticals	99.01%

Insider Ownership

Company	Insider Ownership
APLT Applied Therapeutics	1.60%
CYTK Cytokinetics	2.70%
GOSS Gossamer Bio	6.70%
KPTI Karyopharm Therapeutics	2.98%
PHAT Phathom Pharmaceuticals	23.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLT Applied Therapeutics	30	141.58 million	139.31 million	Optionable
CYTK Cytokinetics	250	119.43 million	116.20 million	Optionable
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	8.38 million	Optionable
PHAT Phathom Pharmaceuticals	110	69.81 million	53.76 million	Optionable

PHAT, APLT, KPTI, CYTK, and GOSS Headlines

Recent News About These Companies

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 7.4% - Here's Why

July 1, 2025 | marketbeat.com

Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism

June 25, 2025 | seekingalpha.com

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - Morningstar

June 24, 2025 | morningstar.comM

Phathom Pharmaceuticals, Inc. (PHAT) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 23, 2025 | globenewswire.com

Phathom Pharmaceuticals Appoints Cook as Chief Legal Officer

June 23, 2025 | news.bloomberglaw.comN

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.8% - Time to Sell?

June 23, 2025 | marketbeat.com

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

June 23, 2025 | globenewswire.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Rating of "Buy" by Brokerages

June 18, 2025 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 4.6% - Should You Sell?

June 16, 2025 | marketbeat.com

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

June 16, 2025 | globenewswire.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up - Should You Buy?

June 12, 2025 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading 6.4% Higher - Should You Buy?

June 11, 2025 | marketbeat.com

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy

June 10, 2025 | seekingalpha.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 9.7% - Here's What Happened

June 9, 2025 | marketbeat.com

Phathom: Share Price Surge On Patent News May Not Stop The Rot For Long

June 9, 2025 | seekingalpha.com

Traders Purchase High Volume of Call Options on Phathom Pharmaceuticals (NASDAQ:PHAT)

June 9, 2025 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Given New $17.00 Price Target at Craig Hallum

June 9, 2025 | marketbeat.com

Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade

June 9, 2025 | zacks.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Given "Buy" Rating at HC Wainwright

June 9, 2025 | marketbeat.com

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032

June 8, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT, APLT, KPTI, CYTK, and GOSS Company Descriptions

Applied Therapeutics NASDAQ:APLT

$0.34 0.00 (-0.38%)

Closing price 07/3/2025 03:50 PM Eastern

Extended Trading

$0.34 0.00 (-0.30%)

As of 07/3/2025 04:59 PM Eastern

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Cytokinetics NASDAQ:CYTK

$33.90 -0.46 (-1.34%)

Closing price 07/3/2025 02:25 PM Eastern

Extended Trading

$34.52 +0.62 (+1.81%)

As of 07/3/2025 04:20 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Gossamer Bio NASDAQ:GOSS

$1.23 +0.02 (+1.24%)

Closing price 07/3/2025 03:47 PM Eastern

Extended Trading

$1.23 0.00 (0.00%)

As of 07/3/2025 04:53 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Karyopharm Therapeutics NASDAQ:KPTI

$4.62 +0.01 (+0.22%)

Closing price 07/3/2025 02:45 PM Eastern

Extended Trading

$4.49 -0.13 (-2.81%)

As of 07/3/2025 04:28 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Phathom Pharmaceuticals NASDAQ:PHAT

$8.76 -0.15 (-1.63%)

Closing price 07/3/2025 03:47 PM Eastern

Extended Trading

$8.87 +0.10 (+1.20%)

As of 07/3/2025 04:39 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time